BDBM384469 US10590114, No. 156::US11111235, Compound 155::US11591316, Compound 155::US9932325, Example 155::US9932325, Example 156
SMILES CNc1nc(Nc2cc(nn2C2CC2)C2(C)CCOC2=O)ncc1C(F)(F)F
InChI Key InChIKey=NKOFNLGIGZSVGZ-UHFFFAOYSA-N
Data 10 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 10 hits for monomerid = 384469
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Denali Therapautics
US Patent
Denali Therapautics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Denali Therapautics
US Patent
Denali Therapautics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: 1.95nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials:LRRK2 G2019S enzymeSubstrate (LRRKtide)ATPTR-FRET dilution bufferpLRRKtide antibody384-well assay plateDMSOEnzyme Reaction Conditions50 mM ...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: 1.95nMAssay Description:Materials:LRRK2 G2019S enzymeSubstrate (LRRKtide)ATPTR-FRET dilution bufferpLRRKtide antibody384-well assay plateDMSOEnzyme Reaction Conditions50 mM ...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: <30nMAssay Description:Materials:LRRK2 G2019S enzymeSubstrate (LRRKtide)ATPTR-FRET dilution bufferpLRRKtide antibody384-well assay plateDMSOEnzyme Reaction Conditions50 mM ...More data for this Ligand-Target Pair